(2S)-N-[(2R)-1-[[(2S)-1-[[(2S,5S,8S,11R,12S,15S,18S,21R)-5-[(3-chloro-4-hydroxyphenyl)methyl]-21-hydroxy-2-[(1R)-1-hydroxyethyl]-4,11-dimethyl-15-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2R)-2,3-dihydroxypropanoyl]amino]-5-(4-hydroxyphenyl)pentanamide
| Internal ID | 5200aeb2-1183-4f73-8727-614c6d8507a6 |
| Taxonomy | Organic acids and derivatives > Peptidomimetics > Depsipeptides > Cyclic depsipeptides |
| IUPAC Name | (2S)-N-[(2R)-1-[[(2S)-1-[[(2S,5S,8S,11R,12S,15S,18S,21R)-5-[(3-chloro-4-hydroxyphenyl)methyl]-21-hydroxy-2-[(1R)-1-hydroxyethyl]-4,11-dimethyl-15-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2R)-2,3-dihydroxypropanoyl]amino]-5-(4-hydroxyphenyl)pentanamide |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C56H82ClN9O17/c1-26(2)22-38-49(75)60-37-19-21-42(72)66(54(37)80)46(30(8)68)55(81)65(10)39(24-33-16-20-40(70)35(57)23-33)50(76)63-44(28(5)6)56(82)83-31(9)45(53(79)61-38)64-52(78)43(27(3)4)62-47(73)29(7)58-48(74)36(59-51(77)41(71)25-67)13-11-12-32-14-17-34(69)18-15-32/h14-18,20,23,26-31,36-39,41-46,67-72H,11-13,19,21-22,24-25H2,1-10H3,(H,58,74)(H,59,77)(H,60,75)(H,61,79)(H,62,73)(H,63,76)(H,64,78)/t29-,30-,31-,36+,37+,38+,39+,41-,42-,43+,44+,45+,46+/m1/s1 |
| InChI Key | DDRDKAKGHUYAPS-HGGGZJIKSA-N |
| Popularity | 3 references in papers |
| Molecular Formula | C56H82ClN9O17 |
| Molecular Weight | 1188.80 g/mol |
| Exact Mass | 1187.5517199 g/mol |
| Topological Polar Surface Area (TPSA) | 392.00 Ų |
| XlogP | 3.30 |
| Atomic LogP (AlogP) | -1.10 |
| H-Bond Acceptor | 17 |
| H-Bond Donor | 13 |
| Rotatable Bonds | 20 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | - | 0.6129 | 61.29% |
| Caco-2 | - | 0.8633 | 86.33% |
| Blood Brain Barrier | - | 0.9000 | 90.00% |
| Human oral bioavailability | - | 0.6286 | 62.86% |
| Subcellular localzation | Lysosomes | 0.4688 | 46.88% |
| OATP2B1 inhibitior | - | 0.8600 | 86.00% |
| OATP1B1 inhibitior | + | 0.8115 | 81.15% |
| OATP1B3 inhibitior | + | 0.9258 | 92.58% |
| MATE1 inhibitior | - | 0.8400 | 84.00% |
| OCT2 inhibitior | - | 0.9500 | 95.00% |
| BSEP inhibitior | + | 0.9228 | 92.28% |
| P-glycoprotein inhibitior | + | 0.7415 | 74.15% |
| P-glycoprotein substrate | + | 0.8830 | 88.30% |
| CYP3A4 substrate | + | 0.7541 | 75.41% |
| CYP2C9 substrate | - | 0.8016 | 80.16% |
| CYP2D6 substrate | - | 0.8444 | 84.44% |
| CYP3A4 inhibition | - | 0.8788 | 87.88% |
| CYP2C9 inhibition | - | 0.8553 | 85.53% |
| CYP2C19 inhibition | - | 0.8451 | 84.51% |
| CYP2D6 inhibition | - | 0.8780 | 87.80% |
| CYP1A2 inhibition | - | 0.9076 | 90.76% |
| CYP2C8 inhibition | + | 0.8066 | 80.66% |
| CYP inhibitory promiscuity | - | 0.9378 | 93.78% |
| UGT catelyzed | + | 0.9000 | 90.00% |
| Carcinogenicity (binary) | - | 0.6900 | 69.00% |
| Carcinogenicity (trinary) | Non-required | 0.5613 | 56.13% |
| Eye corrosion | - | 0.9865 | 98.65% |
| Eye irritation | - | 0.8969 | 89.69% |
| Skin irritation | - | 0.7799 | 77.99% |
| Skin corrosion | - | 0.9311 | 93.11% |
| Ames mutagenesis | - | 0.5454 | 54.54% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.6759 | 67.59% |
| Micronuclear | + | 0.8700 | 87.00% |
| Hepatotoxicity | - | 0.5625 | 56.25% |
| skin sensitisation | - | 0.8668 | 86.68% |
| Respiratory toxicity | + | 0.8444 | 84.44% |
| Reproductive toxicity | + | 0.9111 | 91.11% |
| Mitochondrial toxicity | + | 0.9375 | 93.75% |
| Nephrotoxicity | - | 0.5606 | 56.06% |
| Acute Oral Toxicity (c) | III | 0.6287 | 62.87% |
| Estrogen receptor binding | + | 0.7163 | 71.63% |
| Androgen receptor binding | + | 0.7463 | 74.63% |
| Thyroid receptor binding | + | 0.6669 | 66.69% |
| Glucocorticoid receptor binding | + | 0.6974 | 69.74% |
| Aromatase binding | + | 0.6778 | 67.78% |
| PPAR gamma | + | 0.8121 | 81.21% |
| Honey bee toxicity | - | 0.6623 | 66.23% |
| Biodegradation | - | 0.8250 | 82.50% |
| Crustacea aquatic toxicity | + | 0.5149 | 51.49% |
| Fish aquatic toxicity | + | 0.8334 | 83.34% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL2581 | P07339 | Cathepsin D | 99.94% | 98.95% |
| CHEMBL4072 | P07858 | Cathepsin B | 99.90% | 93.67% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 99.31% | 94.45% |
| CHEMBL3837 | P07711 | Cathepsin L | 99.25% | 96.61% |
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 98.70% | 83.82% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 98.24% | 96.09% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 98.09% | 91.11% |
| CHEMBL5852 | Q96P65 | Pyroglutamylated RFamide peptide receptor | 97.93% | 85.00% |
| CHEMBL226 | P30542 | Adenosine A1 receptor | 97.90% | 95.93% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 97.74% | 90.08% |
| CHEMBL4835 | P00338 | L-lactate dehydrogenase A chain | 96.96% | 95.34% |
| CHEMBL2094135 | Q96BI3 | Gamma-secretase | 95.70% | 98.05% |
| CHEMBL3976 | Q9UHL4 | Dipeptidyl peptidase II | 95.03% | 92.29% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 95.01% | 93.56% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 94.82% | 99.17% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 94.51% | 94.66% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 94.41% | 96.11% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 93.19% | 95.56% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 92.84% | 96.90% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 92.47% | 97.14% |
| CHEMBL236 | P41143 | Delta opioid receptor | 92.04% | 99.35% |
| CHEMBL2000 | P03952 | Plasma kallikrein | 91.92% | 93.92% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 91.87% | 94.75% |
| CHEMBL1949 | P62937 | Cyclophilin A | 91.43% | 98.57% |
| CHEMBL333 | P08253 | Matrix metalloproteinase-2 | 91.43% | 96.31% |
| CHEMBL340 | P08684 | Cytochrome P450 3A4 | 91.40% | 91.19% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 91.18% | 95.89% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 91.02% | 92.88% |
| CHEMBL5966 | P55899 | IgG receptor FcRn large subunit p51 | 90.69% | 90.93% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 90.57% | 97.09% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 90.54% | 90.71% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 90.43% | 95.00% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 90.29% | 89.00% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 90.20% | 95.89% |
| CHEMBL1907594 | P30926 | Neuronal acetylcholine receptor; alpha3/beta4 | 89.41% | 97.23% |
| CHEMBL5939 | Q9NZ08 | Endoplasmic reticulum aminopeptidase 1 | 89.35% | 100.00% |
| CHEMBL1860 | P10827 | Thyroid hormone receptor alpha | 89.04% | 99.15% |
| CHEMBL2563 | Q9UQL6 | Histone deacetylase 5 | 89.02% | 89.67% |
| CHEMBL206 | P03372 | Estrogen receptor alpha | 88.83% | 97.64% |
| CHEMBL2413 | P32246 | C-C chemokine receptor type 1 | 88.43% | 89.50% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 87.44% | 100.00% |
| CHEMBL2553 | Q15418 | Ribosomal protein S6 kinase alpha 1 | 86.94% | 85.11% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 86.55% | 98.59% |
| CHEMBL1795139 | Q8IU80 | Transmembrane protease serine 6 | 86.36% | 98.33% |
| CHEMBL1907600 | Q00535 | Cyclin-dependent kinase 5/CDK5 activator 1 | 85.92% | 93.03% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 85.32% | 96.47% |
| CHEMBL283 | P08254 | Matrix metalloproteinase 3 | 85.14% | 97.29% |
| CHEMBL3004 | P33527 | Multidrug resistance-associated protein 1 | 84.36% | 96.37% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 84.26% | 95.50% |
| CHEMBL2083 | P15090 | Fatty acid binding protein adipocyte | 84.04% | 95.71% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 83.97% | 100.00% |
| CHEMBL4016 | P42262 | Glutamate receptor ionotropic, AMPA 2 | 83.96% | 86.92% |
| CHEMBL5314 | Q06418 | Tyrosine-protein kinase receptor TYRO3 | 83.82% | 96.00% |
| CHEMBL242 | Q92731 | Estrogen receptor beta | 83.75% | 98.35% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 83.12% | 93.00% |
| CHEMBL1907591 | P30926 | Neuronal acetylcholine receptor; alpha4/beta4 | 82.84% | 100.00% |
| CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 82.36% | 86.33% |
| CHEMBL6175 | Q9H3R0 | Lysine-specific demethylase 4C | 82.16% | 96.69% |
| CHEMBL2492 | P36544 | Neuronal acetylcholine receptor protein alpha-7 subunit | 82.14% | 88.42% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 81.84% | 92.32% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 80.87% | 97.64% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 80.49% | 95.71% |
| CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 80.16% | 96.38% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 44448225 |
| LOTUS | LTS0225144 |
| wikiData | Q104976717 |